Esther Mac Donald
About Esther Mac Donald
Esther Mac Donald is the Senior Manager Access & Value Strategy Hematology at Bristol Myers Squibb in München, Germany, with over a decade of experience in Pharma Market Access and Health Policy.
Company: Bristol Myers Squibb
Esther Mac Donald is currently employed at Bristol Myers Squibb, where she holds the position of Senior Manager Access & Value Strategy Hematology. She began her tenure in July 2021 and is based in München, Bayern, Deutschland. In this role, she focuses on developing strategies to improve access and value for hematology products.
Title: Senior Manager Access & Value Strategy Hematology
As the Senior Manager Access & Value Strategy Hematology at Bristol Myers Squibb, Esther Mac Donald is responsible for crafting and implementing strategies that enhance market access and value for hematology products. Her expertise in this field is grounded in her extensive experience in market access and health policy.
Previous Roles at Celgene
Prior to joining Bristol Myers Squibb, Esther Mac Donald worked at Celgene. She held the positions of Senior Manager Market Access from 2018 to 2021 and Manager Market Access from 2014 to 2018. During her time at Celgene, she developed significant expertise in market access strategies within the pharmaceutical industry.
Experience at GlaxoSmithKline
Before her tenure at Celgene, Esther Mac Donald worked at GlaxoSmithKline in various capacities. From 2011 to 2014, she was the Manager Regional Market Access, and prior to that, she served as Manager Gesundheitspolitik from 2009 to 2011. These roles provided her with a strong foundation in regional market access and health policy management.
Education and Expertise: Friedrich-Alexander-Universität Erlangen-Nürnberg
Esther Mac Donald completed her education in Betriebswirtschaftslehre (Business Administration) at Friedrich-Alexander-Universität Erlangen-Nürnberg, earning a Diplom degree in 2009. Her academic background, coupled with over a decade of professional experience, has equipped her with substantial knowledge and skills in the pharmaceutical industry, particularly in market access and health policy.